ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients

Autor: Andrea Picchianti-Diamanti, Alessandra Aiello, Bruno Laganà, Chiara Agrati, Concetta Castilletti, Silvia Meschi, Chiara Farroni, Daniele Lapa, Saeid Najafi Fard, Gilda Cuzzi, Eleonora Cimini, Germana Grassi, Valentina Vanini, Roberta Di Rosa, Simonetta Salemi, Gabriele Nalli, Andrea Salmi, Federica Repele, Anna Maria Gerarda Altera, Gaetano Maffongelli, Claudia Palazzolo, Serena Vita, Sara Leone, Vincenzo Puro, Maria Rosaria Capobianchi, Giuseppe Ippolito, Emanuele Nicastri, Delia Goletti
Jazyk: angličtina
Rok vydání: 2021
Předmět:
CD4-Positive T-Lymphocytes
Male
rheumatoid arthritis
medicine.medical_specialty
COVID-19 Vaccines
T-Lymphocytes
medicine.medical_treatment
Immunology
Antibodies
Viral
Serology
Arthritis
Rheumatoid
Interferon-gamma
Immune system
Internal medicine
medicine
Humans
Immunology and Allergy
Lymphocyte Count
Adverse effect
Aged
Original Research
Vaccines
Synthetic
biology
SARS-CoV-2
DMARD (disease modifying anti-rheumatic drug)
business.industry
whole blood
COVID-19
Immunotherapy
antibody response
Middle Aged
RC581-607
covid-19
mrna vaccine
t cell response
dmard (disease modifying anti-rheumatic drug)
biological therapy
medicine.disease
T cell response
Rheumatology
Vaccination
mRNA vaccine
Rheumatoid arthritis
Spike Glycoprotein
Coronavirus
biology.protein
Female
Antibody
Immunologic diseases. Allergy
business
Zdroj: Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
ISSN: 1664-3224
Popis: ObjectiveTo assess in rheumatoid arthritis (RA) patients, treated with different immunosuppressive therapies, the induction of SARS-CoV-2-specific immune response after vaccination in terms of anti-region-binding-domain (RBD)-antibody- and T-cell-specific responses against spike, and the vaccine safety in terms of clinical impact on disease activity.MethodsHealth care workers (HCWs) and RA patients, having completed the BNT162b2-mRNA vaccination in the last 2 weeks, were enrolled. Serological response was evaluated by quantifying anti-RBD antibodies, while the cell-mediated response was evaluated by a whole-blood test quantifying the interferon (IFN)-γ-response to spike peptides. FACS analysis was performed to identify the cells responding to spike stimulation. RA disease activity was evaluated by clinical examination through the DAS28crp, and local and/or systemic clinical adverse events were registered. In RA patients, the ongoing therapeutic regimen was modified during the vaccination period according to the American College of Rheumatology indications.ResultsWe prospectively enrolled 167 HCWs and 35 RA patients. Anti-RBD-antibodies were detected in almost all patients (34/35, 97%), although the titer was significantly reduced in patients under CTLA-4-inhibitors (median: 465 BAU/mL, IQR: 103-1189, p+ and CD8+ T cells. Finally, no significant increase in disease activity was found in RA patients following vaccination.ConclusionThis study showed for the first time that antibody-specific and whole-blood spike-specific T-cell responses induced by the COVID-19 mRNA-vaccine were present in the majority of RA patients, who underwent a strategy of temporary suspension of immunosuppressive treatment during vaccine administration. However, the magnitude of specific responses was dependent on the immunosuppressive therapy administered. In RA patients, BNT162b2 vaccine was safe and disease activity remained stable.
Databáze: OpenAIRE
Externí odkaz: